Search
Efinaconazole
go.drugbank.com/drugs/DB09040ApprovedInvestigationalIt was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia. … Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis.
Tozinameran
go.drugbank.com/drugs/DB15696ApprovedInvestigational[A225386,L15007] Comirnaty is undergoing evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701). … [L15002] The modRNA is formulated in lipid nanoparticles for administration via intramuscular injection in two doses, three weeks apart.
Clobetasone
go.drugbank.com/drugs/DB13158ApprovedClobetasone is a corticosteroid that is often employed topically as a treatment for a variety of conditions such as eczema, psoriasis, various forms of dermatitis, and also for certain ophthalmologic conditions
Categories: Corticosteroids, Moderately Potent (Group II)Maprotiline
go.drugbank.com/drugs/DB00934ApprovedIt differs from TCAs in that it does not appear to block serotonin reuptake. … Maprotiline is effective at reducing symptoms of anxiety associated with depression.
Varicella zoster vaccine (recombinant)
go.drugbank.com/drugs/DB13924ApprovedInvestigationalClinical trials for Shingrix have shown greater than 90% efficacy in adults aged 50 and older, with 89% efficacy in preventing postherpetic neuralgia in patients 70 years and older and 91% efficacy in … First approved in October 2017 by the Food and Drug Administration, Shingrix is the preferred vaccine for preventing varicella zoster infection in people aged 50 years and older, replacing Zostavax as
Anifrolumab
go.drugbank.com/drugs/DB11976ApprovedInvestigationalAnifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus. … different definitions of autoantibody positivity, making comparison between trials difficult; all trials involve large portions of patients also using corticosteroids, which may alter patient responses in
Categories: Type I Interferon Receptor AntagonistEncainide
go.drugbank.com/drugs/DB01228ApprovedWithdrawnEncainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack. … The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.
Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class IcSynonyms: (±)-4-methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide, 4-Methoxy-N-{2-[2-(1-methyl-piperidin-2-yl)-ethyl]-phenyl}-benzamideAminoglutethimide
go.drugbank.com/drugs/DB00357ApprovedWithdrawnAminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. … An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens.
Cipaglucosidase alfa
go.drugbank.com/drugs/DB16708ApprovedInvestigationalin Pompe disease. … by a deficiency in GAA.
Neon
go.drugbank.com/drugs/DB11589ApprovedNeon may be used in the clinical setting as a diagnostic tracer gas in a gas analyzer for a lung diffusion test. … It is the fifth most abundant chemical element in the universe by mass but a rare element on Earth.